Prime Medicine, Inc.
PRME- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001894562
No open-market purchases or sales by Prime Medicine, Inc. insiders were filed in the last 90 days; 187 institutions reported holding it in 13F filings for Q2 2026, worth $393.5M in total; ARK Invest is the only superinvestor holding it.
Q4 2023 vs. Q3 2023
How the institutions holding Prime Medicine, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 83 | 105 | +22 |
| Shares | 49.5M | 48.7M | −826.1K (−1.7%) |
| Value | $472.3M | $431.4M | −$40.8M (−8.6%) |
New holders (34)
Institutions that held Prime Medicine, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
Sold out (12)
Institutions that held Prime Medicine, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| EcoR1 Capital, LLC | 600,000 | $5.72M |
| Moore Capital Management, LP | 446,733 | $4.26M |
| Rafferty Asset Management, LLC | 128,876 | $1.23M |
| Janus Henderson Group PLC | 120,946 | $1.15M |
| Profund Advisors LLC | 21,995 | $209.8K |
| Penserra Capital Management LLC | 18,468 | $176.0K |
| Virtu Financial LLC | 12,466 | $119.0K |
| Citadel Advisors LLC | 6,524 | $62.2K |
| Allspring Global Investments Holdings, LLC | 3,067 | $29.3K |
| US Bancorp | 346 | $3.30K |
| Grove Bank & Trust | 77 | $735 |
| Massmutual Trust Co FSB | 25 | $239 |